These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26999526)

  • 1. Compliance, Persistence, and Preferences Regarding Osteoporosis Treatment During Active Therapy or Drug Holiday.
    Eliasaf A; Amitai A; Maram Edry M; Yosselson Superstine S; Rotman Pikielny P
    J Clin Pharmacol; 2016 Nov; 56(11):1416-1422. PubMed ID: 26999526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
    Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
    Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
    Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
    Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis.
    Karlsson L; Lundkvist J; Psachoulia E; Intorcia M; Ström O
    Osteoporos Int; 2015 Oct; 26(10):2401-11. PubMed ID: 26282229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to denosumab in the treatment of osteoporosis and its utilization in the Czech Republic.
    Fuksa L; Vytrisalova M
    Curr Med Res Opin; 2015; 31(9):1645-53. PubMed ID: 26121231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States.
    Durden E; Pinto L; Lopez-Gonzalez L; Juneau P; Barron R
    Arch Osteoporos; 2017 Dec; 12(1):22. PubMed ID: 28243883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of persistence and compliance with bisphosphonates for osteoporosis.
    Cramer JA; Gold DT; Silverman SL; Lewiecki EM
    Osteoporos Int; 2007 Aug; 18(8):1023-31. PubMed ID: 17308956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database.
    Confavreux CB; Canoui-Poitrine F; Schott AM; Ambrosi V; Tainturier V; Chapurlat RD
    Eur J Endocrinol; 2012 Apr; 166(4):735-41. PubMed ID: 22258112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence and persistence in patients with severe osteoporosis treated with teriparatide.
    Ziller V; Zimmermann SP; Kalder M; Ziller M; Seker-Pektas B; Hellmeyer L; Hadji P
    Curr Med Res Opin; 2010 Mar; 26(3):675-81. PubMed ID: 20078188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence and profile of non-persistence in patients treated for osteoporosis--a large-scale, long-term retrospective study in The Netherlands.
    Netelenbos JC; Geusens PP; Ypma G; Buijs SJ
    Osteoporos Int; 2011 May; 22(5):1537-46. PubMed ID: 20838773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab.
    Hadji P; Kyvernitakis I; Kann PH; Niedhart C; Hofbauer LC; Schwarz H; Kurth AA; Thomasius F; Schulte M; Intorcia M; Psachoulia E; Schmid T
    Osteoporos Int; 2016 Oct; 27(10):2967-78. PubMed ID: 27172934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up.
    Belhassen M; Confavreux CB; Cortet B; Lamezec L; Ginoux M; Van Ganse E
    Osteoporos Int; 2017 Mar; 28(3):853-862. PubMed ID: 27766368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter.
    Vytrisalova M; Touskova T; Ladova K; Fuksa L; Palicka V; Matoulkova P; Horak P; Stepan J
    Climacteric; 2015; 18(4):608-16. PubMed ID: 25495333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving adherence to and persistence with oral therapy of osteoporosis.
    Bianchi ML; Duca P; Vai S; Guglielmi G; Viti R; Battista C; Scillitani A; Muscarella S; Luisetto G; Camozzi V; Nuti R; Caffarelli C; Gonnelli S; Albanese C; De Tullio V; Isaia G; D'Amelio P; Broggi F; Croci M
    Osteoporos Int; 2015 May; 26(5):1629-38. PubMed ID: 25619634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.
    Fahrleitner-Pammer A; Papaioannou N; Gielen E; Feudjo Tepie M; Toffis C; Frieling I; Geusens P; Makras P; Boschitsch E; Callens J; Anastasilakis AD; Niedhart C; Resch H; Kalouche-Khalil L; Hadji P
    Arch Osteoporos; 2017 Dec; 12(1):58. PubMed ID: 28643265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M; Viapiana O; Gatti D; Adami S
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases.
    Brankin E; Walker M; Lynch N; Aspray T; Lis Y; Cowell W
    Curr Med Res Opin; 2006 Jul; 22(7):1249-56. PubMed ID: 16834823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis.
    Cotté FE; Mercier F; De Pouvourville G
    Clin Ther; 2008 Dec; 30(12):2410-22. PubMed ID: 19167600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to osteoporosis medicines in Estonia-a comprehensive 15-year retrospective prescriptions database study.
    Laius O; Pisarev H; Maasalu K; Kõks S; Märtson A
    Arch Osteoporos; 2017 Dec; 12(1):59. PubMed ID: 28643266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J; Vanuga P; Payer J; Svobodník A
    Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.